ADVA
ADVA (FSE: ADV) today launched its new FSP 3000 data center interconnect (DCI) open line system (OLS) specifically designed for 400ZR technologies. The new DCI OLS addresses the most urgent challenges for network operators by enabling commercial deployments of DCI infrastructure based on 400ZR. These high-density, cost-effective, open solutions that are optimized for point-to-point applications up to 120km will be key to rapidly expanding DCI capacity to meet soaring data demand. Currently undergoing customer testing and evaluation, the ADVA DCI OLS has demonstrated seamless interoperability with 400ZR pluggable transceivers. The solution is fully compliant and even outperforms the 400ZR standard. What’s more, with data center-compatible open APIs, it can be directly integrated into SDN environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005055/en/
“Today we’re announcing a major milestone for open, high-capacity data center networks. The launch of our new DCI OLS will be key for operators. It provides the missing link to real-world deployments of open infrastructure built with 400ZR interfaces,” said Christoph Glingener, CTO, ADVA. “Our pedigree in the DCI space is second to none. We were the original DCI company, enabling Fortune 500 companies around the globe to harness the cloud with best-in-breed solutions. For more than 25 years, our innovation has helped the industry evolve. Now we’re giving large-scale DCI providers what they need to move forward. Our next-generation FSP 3000 DCI OLS offers a way to inject ultra-high capacity while reducing total cost of ownership and operational complexity. What’s more, the ADVA FSP 3000 DCI OLS solution is designed to optimize performance with 400ZR-compliant optics from any vendor.”
The ADVA FSP 3000 DCI OLS is fully compliant with the OIF’s implementation agreement for 400ZR coherent optical interfaces. Optimized for amplified 400Gbit/s DWDM links with reaches up to 120km at 75GHz or 100GHz channel spacing, the solution exceeds all 400ZR performance specifications. It’s also compatible with OpenZR+ interfaces, which expand the application area to DCI applications with distances far beyond 120km. With its open interfaces, the ADVA DCI OLS ensures seamless integration with third-party transceivers and enables network operators to deploy best-of-breed technology. A high level of functional integration minimizes fiber cabling and provides simplified, automated and rapid turnup for optimal performance. The ADVA FSP 3000 DCI OLS integrates multiple diagnostic tools, including built-in OTDR for the monitoring of all fibers and built-in optical channel monitoring. These automated diagnostic capabilities significantly reduce operating costs and improve repair time.
“Omdia is projecting a significant market take-up for 400ZR pluggable technology. 400ZR has many appealing attributes, including multi-vendor interoperability, appealing cost per bit, and a small form factor with low power consumption. Additionally, 400ZR will be practically deployable in switch/routing platforms, enabling the realization of a decades-long service provider dream,” commented Ian Redpath, practice leader, transport networks and components, Omdia. “ADVA has a proven co-development track record in supporting open and innovative DCI solutions. With its new DCI OLS, ADVA is ideally positioned to take the open line system concept to the next level, interworking directly with 400ZR. And with open API support, ADVA will ensure tight integration with cloud and network provider SDN orchestration and control systems.”
Watch this video for more information on the new DCI OLS: https://youtu.be/8zI3E46oMBo .
Further details are also available in these slides: https://adva.li/dci-ols-400zr-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005055/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom